2jkq › Citations

Crystal structures of the FAK kinase in complex with TAE226 and related bis-anilino pyrimidine inhibitors reveal a helical DFG conformation.

Lietha D, Eck MJ
PLoS One 3 e3800 (2008)
Related entries: 2jkk, 2jkm, 2jko

Cited: 45 times
EuropePMC logo PMID: 19030106

Abstract

Focal Adhesion Kinase (FAK) is a non-receptor tyrosine kinase required for cell migration, proliferation and survival. FAK overexpression has been documented in diverse human cancers and is associated with a poor clinical outcome. Recently, a novel bis-anilino pyrimidine inhibitor, TAE226, was reported to efficiently inhibit FAK signaling, arrest tumor growth and invasion and prolong the life of mice with glioma or ovarian tumor implants. Here we describe the crystal structures of the FAK kinase bound to TAE226 and three related bis-anilino pyrimidine compounds. TAE226 induces a conformation of the N-terminal portion of the kinase activation loop that is only observed in FAK, but is distinct from the conformation in both the active and inactive states of the kinase. This conformation appears to require a glycine immediately N-terminal to the "DFG motif", which adopts a helical conformation stabilized by interactions with TAE226. The presence of a glycine residue in this position contributes to the specificity of TAE226 and related compounds for FAK. Our work highlights the fact that kinases can access conformational space that is not necessarily utilized for their native catalytic regulation, and that such conformations can explain and be exploited for inhibitor specificity.

Articles - 2jkq mentioned but not cited (1)

  1. Discovery of novel focal adhesion kinase inhibitors using a hybrid protocol of virtual screening approach based on multicomplex-based pharmacophore and molecular docking. Wu F, Xu T, He G, Ouyang L, Han B, Peng C, Song X, Xiang M. Int J Mol Sci 13 15668-15678 (2012)


Reviews citing this publication (13)

  1. FAK in cancer: mechanistic findings and clinical applications. Sulzmaier FJ, Jean C, Schlaepfer DD. Nat Rev Cancer 14 598-610 (2014)
  2. Targeting extracellular matrix stiffness to attenuate disease: From molecular mechanisms to clinical trials. Lampi MC, Reinhart-King CA. Sci Transl Med 10 eaao0475 (2018)
  3. Targeting focal adhesion kinase signaling in tumor growth and metastasis. Schwock J, Dhani N, Hedley DW. Expert Opin Ther Targets 14 77-94 (2010)
  4. Targeting Pyk2 for therapeutic intervention. Lipinski CA, Loftus JC. Expert Opin Ther Targets 14 95-108 (2010)
  5. How focal adhesion kinase achieves regulation by linking ligand binding, localization and action. Arold ST. Curr Opin Struct Biol 21 808-813 (2011)
  6. Endothelial FAK as a therapeutic target in disease. Infusino GA, Jacobson JR. Microvasc Res 83 89-96 (2012)
  7. The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl. Eck MJ, Manley PW. Curr Opin Cell Biol 21 288-295 (2009)
  8. Structural biology contributions to tyrosine kinase drug discovery. Cowan-Jacob SW, Möbitz H, Fabbro D. Curr Opin Cell Biol 21 280-287 (2009)
  9. Drug Discovery Targeting Focal Adhesion Kinase (FAK) as a Promising Cancer Therapy. Pang XJ, Liu XJ, Liu Y, Liu WB, Li YR, Yu GX, Tian XY, Zhang YB, Song J, Jin CY, Zhang SY. Molecules 26 4250 (2021)
  10. Focal adhesion kinase inhibitors in the treatment of metastatic cancer: a patent review. Shanthi E, Krishna MH, Arunesh GM, Venkateswara Reddy K, Sooriya Kumar J, Viswanadhan VN. Expert Opin Ther Pat 24 1077-1100 (2014)
  11. Targeting Focal Adhesion Kinase Using Inhibitors of Protein-Protein Interactions. Mousson A, Sick E, Carl P, Dujardin D, De Mey J, Rondé P. Cancers (Basel) 10 E278 (2018)
  12. FAK inhibitors as promising anticancer targets: present and future directions. Mustafa M, Abd El-Hafeez AA, Abdelhafeez DA, Abdelhamid D, Mostafa YA, Ghosh P, Hayallah AM, A Abuo-Rahma GE. Future Med Chem 13 1559-1590 (2021)
  13. Kinases as targets for chemical modulators: Structural aspects and their role in spermatogenesis. Jenardhanan P, Mathur PP. Spermatogenesis 4 e979113 (2014)

Articles citing this publication (31)

  1. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Zhou W, Ercan D, Chen L, Yun CH, Li D, Capelletti M, Cortot AB, Chirieac L, Iacob RE, Padera R, Engen JR, Wong KK, Eck MJ, Gray NS, Jänne PA. Nature 462 1070-1074 (2009)
  2. Structure-based discovery of cellular-active allosteric inhibitors of FAK. Tomita N, Hayashi Y, Suzuki S, Oomori Y, Aramaki Y, Matsushita Y, Iwatani M, Iwata H, Okabe A, Awazu Y, Isono O, Skene RJ, Hosfield DJ, Miki H, Kawamoto T, Hori A, Baba A. Bioorg Med Chem Lett 23 1779-1785 (2013)
  3. Development of o-chlorophenyl substituted pyrimidines as exceptionally potent aurora kinase inhibitors. Lawrence HR, Martin MP, Luo Y, Pireddu R, Yang H, Gevariya H, Ozcan S, Zhu JY, Kendig R, Rodriguez M, Elias R, Cheng JQ, Sebti SM, Schonbrunn E, Lawrence NJ. J Med Chem 55 7392-7416 (2012)
  4. The R1275Q neuroblastoma mutant and certain ATP-competitive inhibitors stabilize alternative activation loop conformations of anaplastic lymphoma kinase. Epstein LF, Chen H, Emkey R, Whittington DA. J Biol Chem 287 37447-37457 (2012)
  5. Synthesis of novel diarylamino-1,3,5-triazine derivatives as FAK inhibitors with anti-angiogenic activity. Dao P, Jarray R, Le Coq J, Lietha D, Loukaci A, Lepelletier Y, Hadj-Slimane R, Garbay C, Raynaud F, Chen H. Bioorg Med Chem Lett 23 4552-4556 (2013)
  6. Exploring Ligand Stability in Protein Crystal Structures Using Binding Pose Metadynamics. Fusani L, Palmer DS, Somers DO, Wall ID. J Chem Inf Model 60 1528-1539 (2020)
  7. Allosteric regulation of focal adhesion kinase by PIP₂ and ATP. Zhou J, Bronowska A, Le Coq J, Lietha D, Gräter F. Biophys J 108 698-705 (2015)
  8. Discovery of potential anticancer multi-targeted ligustrazine based cyclohexanone and oxime analogs overcoming the cancer multidrug resistance. Zha GF, Qin HL, Youssif BGM, Amjad MW, Raja MAG, Abdelazeem AH, Bukhari SNA. Eur J Med Chem 135 34-48 (2017)
  9. Discovery and characterization of novel allosteric FAK inhibitors. Iwatani M, Iwata H, Okabe A, Skene RJ, Tomita N, Hayashi Y, Aramaki Y, Hosfield DJ, Hori A, Baba A, Miki H. Eur J Med Chem 61 49-60 (2013)
  10. Inhibition of both focal adhesion kinase and fibroblast growth factor receptor 2 pathways induces anti-tumor and anti-angiogenic activities. Dao P, Jarray R, Smith N, Lepelletier Y, Le Coq J, Lietha D, Hadj-Slimane R, Herbeuval JP, Garbay C, Raynaud F, Chen H. Cancer Lett 348 88-99 (2014)
  11. Synthesis of novel 1,2,4-triazine scaffold as FAK inhibitors with antitumor activity. Dao P, Lietha D, Etheve-Quelquejeu M, Garbay C, Chen H. Bioorg Med Chem Lett 27 1727-1730 (2017)
  12. Design, synthesis and biological evaluation of sulfonamide-substituted diphenylpyrimidine derivatives (Sul-DPPYs) as potent focal adhesion kinase (FAK) inhibitors with antitumor activity. Qu M, Liu Z, Zhao D, Wang C, Zhang J, Tang Z, Liu K, Shu X, Yuan H, Ma X. Bioorg Med Chem 25 3989-3996 (2017)
  13. Selective antagonism of anticancer drugs for side-effect removal. Fernández A, Sessel S. Trends Pharmacol Sci 30 403-410 (2009)
  14. Discovery of antiproliferative and anti-FAK inhibitory activity of 1,2,4-triazole derivatives containing acetamido carboxylic acid skeleton. Mustafa M, Abuo-Rahma GEA, Abd El-Hafeez AA, Ahmed ER, Abdelhamid D, Ghosh P, Hayallah AM. Bioorg Med Chem Lett 40 127965 (2021)
  15. TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells. Otani H, Yamamoto H, Takaoka M, Sakaguchi M, Soh J, Jida M, Ueno T, Kubo T, Asano H, Tsukuda K, Kiura K, Hatakeyama S, Kawahara E, Naomoto Y, Miyoshi S, Toyooka S. PLoS One 10 e0129838 (2015)
  16. A first-in-class anticancer dual HDAC2/FAK inhibitors bearing hydroxamates/benzamides capped by pyridinyl-1,2,4-triazoles. Mustafa M, Abd El-Hafeez AA, Abdelhamid D, Katkar GD, Mostafa YA, Ghosh P, Hayallah AM, Abuo-Rahma GEA. Eur J Med Chem 222 113569 (2021)
  17. Attenuation of murine acute lung injury by PF-573,228, an inhibitor of focal adhesion kinase. Lederer PA, Zhou T, Chen W, Epshtein Y, Wang H, Mathew B, Jacobson JR. Vascul Pharmacol 110 16-23 (2018)
  18. Comparison of LanthaScreen Eu kinase binding assay and surface plasmon resonance method in elucidating the binding kinetics of focal adhesion kinase inhibitors. Mason JL, Spais C, Husten J, Prouty E, Albom MS, Meyer SL, Ator MA, Angeles TS. Assay Drug Dev Technol 10 468-475 (2012)
  19. Exploring the interaction between human focal adhesion kinase and inhibitors: a molecular dynamic simulation and free energy calculations. Zhan JY, Zhang JL, Wang Y, Li Y, Zhang HX, Zheng QC. J Biomol Struct Dyn 34 2351-2366 (2016)
  20. Structure-Based Virtual Screening, Synthesis and Biological Evaluation of Potential FAK-FAT Domain Inhibitors for Treatment of Metastatic Cancer. Kandil SB, Jones SR, Smith S, Hiscox SE, Westwell AD. Molecules 25 E3488 (2020)
  21. Synthesis, biological evaluation, and molecular dynamics (MD) simulation studies of three novel F-18 labeled and focal adhesion kinase (FAK) targeted 5-bromo pyrimidines as radiotracers for tumor. Fang Y, Wang D, Xu X, Liu J, Wu A, Li X, Xue Q, Wang H, Wang H, Zhang H. Eur J Med Chem 127 493-508 (2017)
  22. Focal Adhesion Kinase Directly Interacts with TSC2 Through Its FAT Domain and Regulates Cell Proliferation in Cashmere Goat Fetal Fibroblasts. Zheng X, Bao W, Yang J, Zhang T, Sun D, Liang Y, Li S, Wang Y, Feng X, Hao H, Wang Z. DNA Cell Biol 35 480-488 (2016)
  23. Molecular Docking, Molecular Dynamics Simulations, and Free Energy Calculation Insights into the Binding Mechanism between VS-4718 and Focal Adhesion Kinase. Shi M, Chen T, Wei S, Zhao C, Zhang X, Li X, Tang X, Liu Y, Yang Z, Chen L. ACS Omega 7 32442-32456 (2022)
  24. Multiple steps to activate FAK's kinase domain: adaptation to confined environments? Herzog FA, Vogel V. Biophys J 104 2521-2529 (2013)
  25. Campylobacter jejuni Triggers Signaling through Host Cell Focal Adhesions To Inhibit Cell Motility. Klappenbach CM, Negretti NM, Aaron J, Chew TL, Konkel ME. mBio 12 e0149421 (2021)
  26. Discovery of Novel 2,4-Dianilinopyrimidine Derivatives Containing 4-(Morpholinomethyl)phenyl and N-Substituted Benzamides as Potential FAK Inhibitors and Anticancer Agents. Han C, Shen K, Wang S, Wang Z, Su F, Wu X, Hu X, Li M, Han J, Wu L. Molecules 26 4187 (2021)
  27. Preparation, in vitro and in vivo evaluation, and molecular dynamics (MD) simulation studies of novel F-18 labeled tumor imaging agents targeting focal adhesion kinase (FAK). Fang Y, Wang D, Xu X, Dava G, Liu J, Li X, Xue Q, Wang H, Zhang J, Zhang H. RSC Adv 8 10333-10345 (2018)
  28. [Effect of the focal adhesion kinase inhibitor TAE226 on the epithelial-mesenchymal transition in human oral squamous cell carcinoma cell line]. Zou XY, Zeng Q, Liu P, Nie MH. Hua Xi Kou Qiang Yi Xue Za Zhi 38 17-22 (2020)
  29. How many kinases are druggable? A review of our current understanding. Anderson B, Rosston P, Ong HW, Hossain MA, Davis-Gilbert ZW, Drewry DH. Biochem J 480 1331-1363 (2023)
  30. The amide derivative of anticopalic acid induces non-apoptotic cell death in triple-negative breast cancer cells by inhibiting FAK activation. Chawengrum P, Luepongpatthana N, Thongnest S, Sirirak J, Boonsombat J, Lirdprapamongkol K, Keeratichamroen S, Kongwaen P, Montatip P, Kittakoop P, Svasti J, Ruchirawat S. Sci Rep 13 13456 (2023)
  31. Three-Dimensional-QSAR and Relative Binding Affinity Estimation of Focal Adhesion Kinase Inhibitors. Ghosh S, Cho SJ. Molecules 28 1464 (2023)


Quick links